Literature DB >> 10483993

Noninvasive evaluation of Helicobacter pylori therapy: role of fasting or postprandial gastrin, pepsinogen I, pepsinogen II, or serum IgG antibodies.

M T Al-Assi1, K Miki, J H Walsh, D P Graham, M Asaka, D Y Graham.   

Abstract

OBJECTIVE: We evaluated the potential value of a change in serum IgG antibodies, fasting or meal-stimulated gastrin levels, and pepsinogen I (PGI) or pepsinogen II (PGII) levels for identifying Helicobacter pylori (H. pylori) status after antibiotic therapy.
METHODS: A total of 32 men and one woman with peptic ulcer disease and documented H. pylori infection were enrolled. Fasting and 30-min postprandial blood samples were obtained at 0, 2, 7, 11, 17, 23, 27, and 39 wk of the study and were analyzed for the factors evaluated.
RESULTS: Treatment was successful in 25 patients and failed in seven. Serum IgG antibodies, meal-stimulated gastrin, and both fasting and meal-stimulated pepsinogen I and II levels fell throughout the study, and pepsinogen I:II ratios increased in those whose infection was cured. The mean levels at wk 0 versus wk 7 were: fasting gastrin (fmol/ml) 12.4 and 11, meal-stimulated gastrin 26.5 and 15.4, PGI (ng/ml) 83.7 and 59, PGII (ng/ml) 24.5 and 13.6, PGI/PGII 3.5 and 4.7, and enzyme-linked immunosorbent assay value 4.8 and 4.55. The sensitivity, specificity, and positive and negative predictive values for the data analyzed using different percent changes (e.g., 80%, 50%, and 20%) were calculated. The specificity and sensitivity remained <80% at all time points.
CONCLUSIONS: Despite a significant fall in serum markers of H. pylori infection in groups of individuals, no marker tested could be used to reliably determine posttherapy H. pylori status for individual patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10483993     DOI: 10.1111/j.1572-0241.1999.01359.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  3 in total

1.  Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis.

Authors:  Yoshihisa Urita; Kazuo Hike; Naotaka Torii; Yoshinori Kikuchi; Eiko Kanda; Masahiko Sasajima; Kazumasa Miki
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

Review 2.  Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method".

Authors:  Kazumasa Miki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2011       Impact factor: 3.493

Review 3.  Non-invasive diagnostic tests for Helicobacter pylori infection.

Authors:  Lawrence Mj Best; Yemisi Takwoingi; Sulman Siddique; Abiram Selladurai; Akash Gandhi; Benjamin Low; Mohammad Yaghoobi; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2018-03-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.